CHEK1 and leukemia: Consistent with our previous results using inhibitors that target Chk1 and Chk2 checkpoint kinases [43, 44], the sensitivity to AZD-1775 did not correlate with leukemia subtypes, karyotype, or with the basal expression of WEE1 (data not shown).